UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Experimental validations of the learnable evolution model

Proceedings of the 2000 Congress on Evolutionary Computation. CEC00 (Cat. No.00TH8512), 2000, Vol.2, p.1064-1071 vol.2

2000

Volltextzugriff (PDF)

Dystrophia myotonica with associated sprue-like symptoms

The American journal of medicine, 1954-04, Vol.16 (4), p.614-616

1954

Volltextzugriff (PDF)

Clinical evaluation of T2 values of patellar cartilage in patients with osteoarthritis

Osteoarthritis and cartilage, 2007-02, Vol.15 (2), p.198-204

2007

Volltextzugriff (PDF)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Cancer Immunology, Immunotherapy, 2016-12, Vol.65 (12), p.1533-1544

2016

Volltextzugriff (PDF)

Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis

Clinical lymphoma, myeloma and leukemia, 2023-04, Vol.23 (4), p.279-290

2023

Volltextzugriff (PDF)

Clinical evaluation of T 2 values of patellar cartilage in patients with osteoarthritis

Osteoarthritis and cartilage, 2007-02, Vol.15 (2), p.198-204

2007

Volltextzugriff (PDF)

High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR)

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.423-423

2015

Volltextzugriff (PDF)

High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.624-624

2018

Volltextzugriff (PDF)

Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e20071-e20071

2015

Volltextzugriff (PDF)

Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIMHD IL-2 National Registry

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15609-e15609

2015

Volltextzugriff (PDF)

Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e21039-e21039

2016

Volltextzugriff (PDF)

Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4548-4548

2016

Volltextzugriff (PDF)

Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIM SM registry

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9528-9528

2017

Volltextzugriff (PDF)

Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.511-511

2016

Volltextzugriff (PDF)

Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4578-4578

2018

Volltextzugriff (PDF)

Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9054-9054

2014

Volltextzugriff (PDF)

High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4523-4523

2014

Volltextzugriff (PDF)

Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

Clinical genitourinary cancer, 2017-02, Vol.15 (1), p.31-41.e4

2017

Volltextzugriff (PDF)

High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes

Journal of clinical oncology, 2014-02, Vol.32 (4_suppl), p.430-430

2014

Volltextzugriff (PDF)

P61 Examiner repeatability of patellar cartilage T2 values

Osteoarthritis and cartilage, 2007, Vol.15, p.B103-B103

2007

Volltextzugriff (PDF)

Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.B140-B140

2016

Volltextzugriff (PDF)

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM

Clinical genitourinary cancer, 2017-02, Vol.15 (1), p.31-41.e4

2017

Volltextzugriff (PDF)

P327 CORRELATION OF KNEE PAIN, FUNCTION, AND HEALTH-RELATED QUALITY OF LIFE MEASURES WITH RADIOGRAPHIC FINDINGS AND PHYSICAL PARAMETERS IN KNEE OSTEOARTHRITIS

Osteoarthritis and cartilage, 2006, Vol.14, p.S177-S177

2006

Volltextzugriff (PDF)

An unusual cystic appearance of disseminated low-grade gliomas

Neuroradiology, 2001-10, Vol.43 (10), p.868-874

2001

Volltextzugriff (PDF)

Influence of diandric and digynic triploid genotypes on early mouse embryogenesis

Development (Cambridge), 1989-01, Vol.105 (1), p.137-145

1989

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(25)
Tagungsberichte
(2)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(9)
Life Sciences & Biomedicine
(8)
Humans
(6)
Female
(5)
Male
(5)
Adult
(3)
Aged
(3)
Magnetic Resonance Imaging
(3)
Middle Aged
(3)
Oncology
(3)
Rheumatology
(3)
Antineoplastic Agents - Administration & Dosage
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Biological And Medical Sciences
(2)
Carcinoma, Renal Cell - Drug Therapy
(2)
Computer Science
(2)
Costs
(2)
Engineering
(2)
Engineering, Electrical & Electronic
(2)
Fourier Transforms
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Experimental validations of the learnable evolution model

Dystrophia myotonica with associated sprue-like symptoms

Clinical evaluation of T2 values of patellar cartilage in patients with osteoarthritis

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis

Clinical evaluation of T 2 values of patellar cartilage in patients with osteoarthritis

High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR)

High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry

Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry

Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIMHD IL-2 National Registry

Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2

Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry

Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIM SM registry

Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2)

Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM

Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry

High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR)

Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes

P61 Examiner repeatability of patellar cartilage T2 values

Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM

P327 CORRELATION OF KNEE PAIN, FUNCTION, AND HEALTH-RELATED QUALITY OF LIFE MEASURES WITH RADIOGRAPHIC FINDINGS AND PHYSICAL PARAMETERS IN KNEE OSTEOARTHRITIS

An unusual cystic appearance of disseminated low-grade gliomas

Influence of diandric and digynic triploid genotypes on early mouse embryogenesis

Suchergebnisse filtern